SureTrader Advertisement
Home > Boards > US Listed > Biotechs > Arena Pharmaceuticals, Inc. (ARNA)

orexigen is no compensation at this point whatsoever period.

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
lovethatgreen Member Profile
Member Level 
Followed By 220
Posts 25,099
Boards Moderated 0
Alias Born 08/07/04
160x600 placeholder
Current Report Filing (8-k) "Edgar (US Regulatory)" - 7/19/2016 9:02:07 AM
Eisai Inc. and Arena Pharmaceuticals Announce FDA Approval of BELVIQ XR® (lorcaserin HCl) Extended-Release Tablets "PR Newswire (US)" - 7/19/2016 8:26:00 AM
Eisai and Arena Pharmaceuticals Announce Regulatory Approval of VENESPRI® (lorcaserin HCl) in Mexico "PR Newswire (US)" - 7/14/2016 8:05:00 AM
Notice of Effectiveness (effect) "Edgar (US Regulatory)" - 7/6/2016 6:02:10 AM
U.S. Hot Stocks: Hot Stocks to Watch "Dow Jones News" - 7/1/2016 9:45:00 AM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 6/30/2016 4:17:13 PM
Arena Pharmaceuticals Announces Shift to Focus on Proprietary Clinical Stage Pipeline "PR Newswire (US)" - 6/30/2016 4:05:00 PM
How These Biotech's Stocks are Performing? - Intrexon, Vertex Pharma, Arena Pharma, and Regeneron Pharma "PR Newswire (US)" - 6/23/2016 7:30:00 AM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 6/16/2016 6:07:05 AM
Arena Pharmaceuticals Announces Appointment of Kevin R. Lind as Chief Financial Officer "PR Newswire (US)" - 6/15/2016 7:00:00 AM
Securities Registration Statement (simplified Form) (s-3/a) "Edgar (US Regulatory)" - 6/15/2016 6:09:36 AM
Securities Registration: Employee Benefit Plan (s-8) "Edgar (US Regulatory)" - 6/14/2016 4:37:15 PM
Securities Registration Statement (simplified Form) (s-3) "Edgar (US Regulatory)" - 6/14/2016 4:35:02 PM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 6/13/2016 4:41:15 PM
Arena Pharmaceuticals Announces USAN Approval of Nonproprietary Name "Etrasimod" for its Drug Candidate APD334 "PR Newswire (US)" - 6/13/2016 7:00:00 AM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 6/10/2016 4:23:41 PM
Quarterly Report (10-q) "Edgar (US Regulatory)" - 5/9/2016 5:50:49 PM
Additional Proxy Soliciting Materials (definitive) (defa14a) "Edgar (US Regulatory)" - 5/9/2016 5:27:55 PM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 5/9/2016 5:14:44 PM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 5/9/2016 5:05:36 PM
Arena Pharmaceuticals Reports First Quarter 2016 Financial Results and Provides Corporate Update "PR Newswire (US)" - 5/9/2016 4:05:00 PM
Arena Pharmaceuticals Announces Appointment of Amit D. Munshi as President and Chief Executive Officer "PR Newswire (US)" - 5/9/2016 4:05:00 PM
Arena Pharmaceuticals to Host First Quarter 2016 Financial Results and Corporate Update Conference Call and Webcast on Monday... "PR Newswire (US)" - 5/2/2016 4:05:00 PM
Additional Proxy Soliciting Materials (definitive) (defa14a) "Edgar (US Regulatory)" - 4/28/2016 4:40:13 PM
Proxy Statement (definitive) (def 14a) "Edgar (US Regulatory)" - 4/28/2016 4:22:41 PM
lovethatgreen Member Level  Monday, 05/14/12 08:57:20 AM
Re: gixxer11 post# 4348
Post # of 22270 
orexigen is no compensation at this point whatsoever period.

and vvus at the stage theyre at, is at a disadvantage in several ways

no manufacturing set up....the risks with the drug are numerous combined with detox requirements after 90 days

I could go on

SureTrader
Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist